Fatigue is a common symptom reported by patients with chronic immunoinflammatory diseases and with profound negative implications on health-related quality of life. This study aimed to delineate un...
Objective Physicians tend to focus on biomedical targets while little is known about issues important to patients. We aimed to identify critical concepts impacting patients with inflammatory bowel disease (IBD). Design We performed a survey of patients with IBD in biologic therapy (n=172) and used a validated qualitative method called group concept mapping (GCM) in patient workshops. The survey included 13 questions on attitudes toward symptoms and issues related to IBD. In the eight workshops, patients (n=26) generated statements later clustered into concepts identifying issues impacting a patient’s life. Patients ranked the statements. Results In the survey, patients’ mean age were 40 years (SD 13), 53% were women, and 38% had ulcerative colitis. They identified fatigue (57%) and stool frequency (46%) as the most critical symptoms impacting their daily lives regardless of disease activity. In the GCM workshops with Crohn’s disease (n=13) (median age 42 years (IQR 39–51) and 62% were women), 335 statements divided among 10 concepts were generated, and the three most important concepts were ‘Positive attitudes’, ‘Accept and recognition’, and ‘Sharing knowledge and experiences in life with Crohn’s disease’. In the workshops with ulcerative colitis (n=13) (median age 43 years (IQR 36–49) and 69% were women), 408 statements divided into 11 concepts were generated; the most important concepts were ‘Take responsibility and control over your life’, ‘Medication’, and ‘Everyday life with ulcerative colitis’. Conclusion Focusing solely on IBD symptoms, patients identified fatigue and stool frequency to impact daily life the most. However, when investigating the disease burden in a broader perspective beyond classic IBD symptoms, patients identified concepts with focus on emotional health to be most important. Trial registration The Copenhagen University Hospital, Herlev and Gentofte approved the questionnaire and methodology (work-zone no: 18015429).
13 November 2021 in Scandinavian Journal of Gastroenterology
Treatment of patients with inflammatory bowel disease (IBD) should aim at achieving mucosal healing. However, monitoring schedules to support this goal remain undefined. We aimed to identify patien...
PURPOSE: Patients with intestinal inflammatory diseases such as ulcerative colitis (UC), Crohn's disease (CD), and microscopic colitis (MC) are excluded from clinical trials with immune checkpoint inhibitors (ICI) because of concerns of exacerbating their underlying immune-mediated disease. This study evaluated the risk of developing disease activity or checkpoint inhibitor checkpoint inhibitor-mediated enterocolitis (IMC). MATERIALS AND METHODS: We performed a nationwide, retrospective cohort study in Denmark, analyzing patients with UC, CD, and MC diagnosed with cancer and treated with ICIs between 2010 and 2024. RESULTS: Eighty-five patients were included, and IMC was observed in 39 (46%) patients. Of these, 15 cases were mild, allowing 61 (72%) patients to continue ICI treatment. Multivariate logistic analysis showed that patients with CD had a lower odds ratio (OR) for developing IMC compared with patients with UC and MC (OR, 0.07, P = .02). When compared with a control cohort without intestinal disease (n = 81), patients with UC, CD, and MC had a significantly higher risk of developing IMC when treated with anti–PD-1/anti–PD-L1 inhibitors, with a hazard ratio of 4.93, P < .001. CONCLUSION: Patients with CD appear to have a lower risk of IMC than those with UC and MC. Despite an increased risk of IMC and severe IMC in patients with UC, CD, and MC, 72% of the patients were able to continue first-line treatment with ICI. Treatment with ICI in patients with UC, CD, and MC is overall well tolerated and should be considered on the basis of the same criteria as in patients without intestinal diseases.
Background/Objectives: The combined goal of achieving both clinical and endoscopic remission has highlighted the need for strategies that support a treat-to-target approach in inflammatory bowel disease (IBD). A proactive monitoring strategy involves scheduled assessments regardless of symptoms to detect subclinical disease activity and enable timely treatment adjustments, whereas a reactive approach initiates evaluation only in response to clinical deterioration or objective signs of active disease. This study investigated whether proactive monitoring improves the achievement of treatment goals compared with a reactive strategy. Methods: In this prospective cohort study carried out between September 2020 and July 2022, patients with IBD receiving biologic therapy were managed according to a predefined proactive monitoring schedule and prospectively followed for one year. A control group, matched for age, sex, diagnosis, and treatment, was enrolled from another tertiary IBD center using a reactive monitoring strategy; their clinical course over one year was reconstructed retrospectively from medical records. All patients underwent colonoscopy assessment at one year. The primary outcome was treatment failure, defined as inadequate mucosal healing or symptom control, the need for intestinal surgery, or discontinuation of biologic therapy due to insufficient efficacy. Results: A total of 162 patients were included (91 managed proactively and 71 managed reactively). In the intention-to-treat population, treatment failure occurred in 67 patients (74%, 95% confidence interval (CI) 63–84%) in the intervention group and 60 patients (85%, 95% CI 75% to 94%) in the control group (difference 11%, CI −3% to 25%, p = 0.13). In the per-protocol analysis, 44 of 69 patients (64%, CI 50% to 78%) in the intervention group experienced treatment failure compared with 43 of 53 patients (81%, CI 60% to 93%) in the control group (difference 17%, CI −1% to 36%, p = 0.06). Patients in the proactive monitoring group underwent significantly more disease-monitoring assessments than those managed reactively. Conclusions: Proactive monitoring numerically improved combined clinical and endoscopic outcomes compared with reactive management, but this did not reach statistical significance and resulted in substantially greater healthcare resource utilization.
Background: Physicians tend to focus on biomedical targets (endoscopic remission), while little is known about issues important to patients. We aimed to identify critical concepts impacting inflammatory bowel disease (IBD) patients.Methods: We performed a survey of patients with IBD in biologic therapy (n=172) and used a validated qualitative method called concept mapping (CM) in patient workshops. The survey included 13 questions on attitudes toward symptoms and issues related to IBD. In the eight CM workshops, patients (n=26) generated statements later clustered into concepts identifying issues impacting a patient’s life. Patients ranked the statements by importance.Results: In the questionnaire survey, patients identified fatigue (57%) and stool frequency (46%) as the most critical symptoms impacting their daily lives regardless of disease activity. In the CM workshops with Crohn’s disease (n=13), 335 statements divided among ten concepts were generated, and the three most important concepts were “Positive attitudes,” (mean 4.3) “Accept and recognition” (mean 4), and “Personal experiences with Crohn’s disease,” (mean 4). In the workshops with ulcerative colitis (n=13), 408 statements divided into 11 concepts were generated; the most important concepts were “Take responsibility and control over your life” (mean 4), “Medication” (mean 3.9), and “Everyday life with ulcerative colitis” (mean 3.7)Conclusion: While symptoms such as fatigue and stool frequency impacted daily life regardless of disease activity, patients with IBD rated concepts focusing on psychosocial factors as having the most significant impact on everyday life.Trial registration: The Copenhagen University Hospital, Herlev and Gentofte approved the questionnaire and methodology (work-zone no.: 18015429).